Therapeutic Efficacy and Feasibility Study of Abbott's BurstDR Spinal Cord Stimulators Technology for Painful Diabetic Neuropathy (PDN)
Therapeutic Efficacy and Feasibility Study of Abbott's BurstDR Spinal Cord Stimulators Technology for Painful Diabetic Neuropathy (PDN) is a NA clinical asset sponsored by TriCity Research Center in Painful Diabetic Neuropathy (PDN), Diabetic Neuropathy, Neuropathic Pain, Chronic Pain. SEO and diligence focus: BurstDR Spinal Cord Stimulation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Painful Diabetic Neuropathy (PDN)
Modality: RNA therapy
Target: BurstDR Spinal Cord Stimulation
Sponsor: TriCity Research Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BurstDR Spinal Cord Stimulation
View original source fields
Condition raw: Painful Diabetic Neuropathy (PDN), Diabetic Neuropathy, Neuropathic Pain, Chronic Pain
Condition normalized: Painful Diabetic Neuropathy (PDN), Diabetic Neuropathy, Neuropathic Pain, Chronic Pain
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: BurstDR Spinal Cord Stimulation
Target normalized: BurstDR Spinal Cord Stimulation